Healthcare: Top Picks Q4 2013 – High selectivity limits choices to two : Qiagen and Fresenius SE

News published on October Tuesday 8, 2013
Share on

Despite an expected approval of Opsumit in October in the US (and potentially a CHMP decision in December), we are removing Actelion from our Top Pick List for Q4 after its strong performance. Next stage in the story is now dependent on selexipag and execution which are more 2014 topics.


Full report available to subscribers

Please contact marketing@bryangarnier.fr  

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities